Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Association of tumor-informed ctDNA-based molecular residual disease (MRD) with clinical outcomes for upper tract urothelial cancer (UTUC).

ctDNA detection was 70.8% in the MRD window (n=24) and 68.8% during surveillance (n=32). Positivity was associated with inferior RFS (MRD window HR 13.4, P=0.012; surveillance HR 14.46, P=0.01). 12-month RFS was 32.1% and 45.5% if positive vs 100% if negative in those windows. On multivariate analysis during surveillance, ctDNA positivity was the only factor significantly associated with poor RFS (HR 17.6, P=0.011).

ASCO Annual Meeting 2025